# reload+after+2024-01-19 23:47:47.755061
address1§160 Second Street
address2§Floor 3
city§Cambridge
state§MA
zip§02142
country§United States
phone§617 830 3031
website§https://www.vbivaccines.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
fullTimeEmployees§190
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Jeffery R. Baxter FCMA', 'age': 62, 'title': 'President, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 908059, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David Evander Anderson', 'age': 53, 'title': 'Chief Scientific Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 534250, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Francisco  Diaz-Mitoma FRCPC, M.D., Ph.D.', 'age': 68, 'title': 'Chief Medical Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 544517, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nell  Beattie', 'age': 35, 'title': 'CFO, Head of Corporate Development & Director', 'yearBorn': 1988, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Nicole  Anderson', 'title': 'Director of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Athena  Kartsaklis', 'age': 58, 'title': 'Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Avi  Mazaltov', 'age': 61, 'title': 'Global Head of Manufacturing & GM of SciVac', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Misha  Nossov', 'title': 'Senior VP of Global Commercial Supply Strategy & Head of Europe', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. T. Adam Buckley', 'age': 47, 'title': 'Senior Vice President of Business Development', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Robert Dillman', 'age': 55, 'title': 'Chief Commercial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.953
priceToSalesTrailing12Months§1.8125962
currency§USD
dateShortInterest§1702598400
forwardEps§-0.82
exchange§NCM
quoteType§EQUITY
shortName§VBI Vaccines, Inc.
longName§VBI Vaccines Inc.
firstTradeDateEpochUtc§1272288600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ce04a43e-8d67-3bb0-a8ad-75cd1a28c328
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§0.509
grossMargins§-0.58729
ebitdaMargins§0.0
trailingPegRatio§None
